Table 1.
Baseline Characteristics (n = 66)
| Variable | Total |
|---|---|
| Age, mean (SD), y | 73.4 (9.3) |
|
| |
| Male, No. (%) | 66 (100) |
|
| |
| HbA1c, mean (SD), % | 6.9 (0.9) |
|
| |
| Diabetes mellitus agents, No. (%) | |
| Average No. of agents | 1.3 |
| Metformin | 33 (50) |
| Sulfonylurea | 24 (36.4) |
| DPP-4 inhibitor | 0 (0) |
| GLP-1 agonist | 0 (0) |
| Thiazolidinedione | 1 (1.5) |
| Insulin glargine | 3 (4.5) |
| Insulin detemir | 0 (0) |
| Insulin NPH | 15 (22.7) |
| Insulin 70/30 | 5 (7.6) |
| Insulin regular | 5 (7.6) |
| Insulin aspart | 3 (4.5) |
|
| |
| Interacting medication (diltiazem, erythromycin, fluconazole, verapamil), No. (%) | 0 (0) |
|
| |
| Ranolazine dose, No. (%) | |
| 500 mg twice daily | 52 (78.8) |
| 1,000 mg twice daily | 14 (21.2) |
|
| |
| Ranolazine possession ratio, %a | 80.4 |
Abbreviations: DPP-4, dipeptidyl pedtidase-4; GLP-1, glucagon-like peptide-1; HbA1C, hemoglobin A1C; NPH, neutral protomine Hagedorn.
a
Total number of days patient was in possession of ranolazine between initiation date and follow-up HbA1c ÷ total number of days between ranolazine initiation date and follow-up HbA1c.